Medical therapy for asymptomatic men with benign prostatic hyperplasia: Primum non nocere

Urology

Volumn 62, Issue 5, 2003, Pages 784-785

  Kaplan, Steven A ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; OXIDOREDUCTASE INHIBITOR; STEROID 5ALPHA REDUCTASE INHIBITOR;

ALPHA ADRENERGIC RECEPTOR BLOCKING; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE PREDISPOSITION; EDITORIAL; FOLLOW UP; GROUPS BY AGE; HUMAN; INCIDENCE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK FACTOR; URINE RETENTION; URODYNAMICS;

EID: 0242664241     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00771-4     Document Type: Editorial

References (9)

1. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
2. McConnell J.D. The long term effects of medical therapy on the progression of LUTS results from the MTOPS trial. J Urol. 167:2002;1042.
3. Berry S.J., Coffey D.S., Walsh P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol. 132:1984;474-479.
4. Garraway W.M., Russell E.B.A.W., Lee R.J., et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract. 43:1993;318-321.
5. Jacobsen S.J., Girman C.J., Leiber M.M. Natural history of benign prostatic hyperplasia. Urology. 58:2001;5-16.
6. Sarma A.V., Jacobsen S.J., Girman C.J., et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol. 168:2002;1446-1452.
7. Walker R.M.H., Romano G., Davies A.H., et al. Pressure flow study data in a group of asymptomatic male control patients 45 years old or older. J Urol. 165:2001;683-687.
8. Tubaro A., Carter S., Trucchi A., et al. Early treatment of benign prostatic hyperplasia implications for reducing the risk of permanent bladder damage. Drugs Aging. 20:2003;185-195.
9. Kaplan S.A., Goluboff E.T., Olsson C.A., et al. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology. 45:1995;398-405.